甲状腺癌相关基因及其在临床诊断中应用的研究进展

doi:10.13481/j.1671-587x.20180436

摘要/Abstract

摘要： 甲状腺癌是发病率逐年上升的来源于内分泌系统的恶性肿瘤之一，v-raf鼠类肉瘤滤过性病毒致癌基因同源体B1（BRAF）、RAS、转染中重排（RET）、端粒酶逆转录酶（TERT）和p53等许多基因均与甲状腺癌的发生发展有密切关联，且对于甲状腺癌的诊断有着重要的意义，通过现有的一些基因检测手段可以对相应的基因进行检测，同时多基因联合检测可以提高检测的灵敏性和特异性，有效地提高甲状腺结节性质预测的准确率。不同的基因改变影响着肿瘤的易感因素、病理分型、恶性程度、转移方式和预后等。现有的甲状腺癌的诊断方法仍有许多局限性，分子水平上的检测和诊断手段也存在着许多不足，一些新的检测方法和实验研究在实际应用中缺乏稳定性。本文作者对甲状腺癌相关基因进行基因水平的分析，介绍相关的检测方法并且阐述甲状腺癌相关基因作为诊断指标的研究情况。

关键词: 甲状腺肿瘤, 甲状腺癌相关基因, 基因突变, 基因检测

中图分类号:

R736.1

魏佳, 王瑶琪, 孙旭, 逄仁柱, 杨帅, 石亮, 李勇, 孟宪瑛. 甲状腺癌相关基因及其在临床诊断中应用的研究进展[J]. 吉林大学学报(医学版), 2018, 44(04): 880-885.

参考文献

[1] O'Grady TJ,Gates MA,Boscoe FP. Thyroid cancer incidence attributable to overdiagnosis in the United States 1981-2011[J].Int J Cancer,2015,137(11):2664-2673.
[2] 张波,徐景竹,吴琼.2015年美国甲状腺学会《成人甲状腺结节与分化型甲状腺癌诊治指南》解读:超声部分[J].中国癌症杂志,2016,26(1):19-24.
[3] Liu M,Ruan M,Chen L.Update on the molecular diagnosis and targeted therapy of thyroid cancer[J].Med Oncol,2014,31(6):973.
[4] Nikiforov YE.Thyroid carcinoma:molecular pathways and therapeutic targets[J].Modern Pathol,2008,21(Suppl 2):S37-S43.
[5] Nucera C,Porrello A,Antonello ZA,et al.B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression[J].Proc Natl Acad Sci USA,2010,107(23):10649-10654.
[6] Kim BA,Jee HG,Yi JW,et al.Expression profiling of a human thyroid cell Line Stably Expressing the BRAFV600E Mutation[J].Cancer Genomics Proteomics,2017,14(1):53-67.
[7] Jung CK,Im SY,Kang YJ,et al.Mutational patterns and novel mutations of the BRAF gene in a large cohort of Korean patients with papillary thyroid carcinoma[J].Thyroid,2012,22(8):791-797.
[8] Xing M.BRAF mutation in thyroid cancer[J].EndocrRelat Cancer,2005,12(2):245-262.
[9] 石臣磊,秦华东,丁超,等.鼠类肉瘤滤过性毒菌致癌同源体B1 V600 E基因突变与甲状腺乳头状癌中央区淋巴结转移的关系[J].中华肿瘤杂志,2015,37(2):123-127.
[10] 王波,赵文新.ret/PTC3基因重排在甲状腺癌中的作用机制及其研究进展[J].中华实验外科杂志,2013,30(10):2241-2242.
[11] Penna GC,Vaisman F,Vaisman M,et al.Molecular markers involved in tumorigenesis of thyroid carcinoma:focus on aggressive histotypes[J].Cytogenet Genome Res,2016,150(3/4):194-207.
[12] Su X,Li Z,He C,et al.Radiation exposure,young age,and female gender are associated with high prevalence of RET/PTC1 and RET/PTC3 in papillary thyroid cancer:a meta-analysis[J].Oncotarget,2016,7(13):16716-16730.
[13] Figlioli G,Landi S,Romei C,et al.Medullary thyroid carcinoma (MTC) and RET proto-oncogene:mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form[J].Mutat Res,2013,752(1):36-44.
[14] Romei C,Cosci B,Renzini G,et al.RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC)[J].Clin Endocrinol(Oxf),2011,74(2):241-247.
[15] Ciriello G,Cerami E,Sander C,et al.Mutual exclusivity analysis identifies oncogenic network modules[J].Genome Res,2012,22(2):398-406.
[16] Nikiforov YE,Nikiforova MN.Molecular genetics and diagnosis of thyroid cancer[J].Nat Rev Endocrinol,2011,7(10):569-580.
[17] Cifuentes-Rojas C,Shippen DE.Telomerase regulation[J].Mutat Res,2012,730(1/2):20-27.
[18] Horn S,Figl A,Rachakonda PS,et al.TERT promoter mutations in familial and sporadic melanoma[J].Science,2013,339(6122):959-961.
[19] Landa I,Ibrahimpasic T,Boucai L,et al.Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers[J].J Clin Invest,2016,126(3):1052-1066.
[20] Xing M,Liu R,Liu X,et al.BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence[J].J Clin Oncol,2014,32(25):2718-2726.
[21] Bullock M,Ren Y,O'Neill C,et al.TERT promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas[J].Clin Endocrinol(Oxf),2016,85(2):283-290.
[22] Pavelic K,Dedivitis RA,Kapitanovic S,et al.Molecular genetic alterations of FHIT and p53 genes in benign and malignant thyroid gland lesions[J].Mutat Res,2006,599(1/2):45-57.
[23] Corapcioglu D,Sak SD,Delibasi T,et al.Papillary microcarcinomas of the thyroid gland and immunohistochemical analysis of expression of p53 protein in papillary microcarcinomas[J].J Transl Med,2006,4:28.
[24] Hasbek Z,Turgut B,Erselcan T.p53 antibody:is it an indicator of dedifferentiated thyroid cancer?[J]. Ann Nucl Med,2014,28(1):42-46.
[25] Balta AZ,Filiz AI,Kurt Y,et al.Prognostic value of oncoprotein expressions in thyroid papillary carcinoma[J].Med Oncol,2012,29(2):734-741.
[26] Tavares C,Melo M,Cameselle-Teijeiro JM,et al.Endocring tumours:Genetic predictors of thyroid cancer outcome[J].Eur J Endocrinol,2016,174(4):R117-126.
[27] Omur O,Baran Y.An update on molecular biology of thyroid cancers[J].Crit Rev Oncol Hematol,2014,90(3):233-252.
[28] Kalhori V,Tornquist K.MMP2 and MMP9 participate in S1P-induced invasion of follicular ML-1 thyroid cancer cells[J].Mol Cell Endocrinol,2015,404:113-122.
[29] 华特波,孟宪瑛,王广义,等.甲状腺组织中COX-2、MMP-9、VEGF和RET的检测及其在甲状腺乳头状癌早期诊断中的意义[J].吉林大学学报:医学版,2011,37(4):712-717.
[30] Gilbert-Sirieix M,Makoukji J,Kimura S,et al.Wnt/beta-catenin signaling pathway is a direct enhancer of thyroid transcription factor-1 in human papillary thyroid carcinoma cells[J].PLoS One,2011,6(7):e22280.
[31] Pacifico F,Leonardi A.Role of NF-kappaB in thyroid cancer[J].Mol Cell Endocrinol,2010,321(1):29-35.
[32] Cancer Genome Atlas Research.Integrated genomic characterization of papillary thyroid carcinoma[J].Cell,2014,159(3):676-690.
[33] Malapelle U,Bellevicine C,Salatiello M,et al.Sanger sequencing in routine KRAS testing:a review of 1720 cases from a pathologist's perspective[J].J Clin Pathol,2012,65(10):940-944.
[34] Schiavo S,Yang WC,Chin NH,et al.Comparison of fluorometric detection methods for quantitative polymerase chain reaction (PCR)[J].J Immunoassay Immunochem,2005,26(1):1-12.
[35] Okayama N,Fujimura K,Nakamura J,et al.Evaluation of a new efficient procedure for single-nucleotide polymorphism genotyping:tetra-primer amplification refractory mutation system-polymerase chain reaction[J].Clin Chem Lab Med,2004,42(1):13-16.
[36] Oler G,Ebina KN,Michaluart PJr,et al.Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis reveals a new mutation in metastasis[J].Clin Endocrinol(Oxf),2005,62(4):509-511.
[37] Zatelli MC,Trasforini G,Leoni S,et al.BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies[J].Eur J Endocrinol,2009,161(3):467-473.
[38] Xing M,Alzahrani AS,Carson KA,et al.Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer[J].JAMA,2013,309(14):1493-1501.
[39] Hsiao SJ,Nikiforov YE.Molecular approaches to thyroid cancer diagnosis[J].Endocrine Relat Cancer,2014,21(5):T301-313.
[40] Fenton CL,Lukes Y,Nicholson D,et al.The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults[J].J Clin Endocrinol Metab,2000,85(3):1170-1175.
[41] Nikiforov YE.RET/PTC rearrangement in thyroid tumors[J].Endocr Pathol,2002,13(1):3-16.
[42] Agarwal S,Agarwal A,Chand G,et al.MEN 2A family——prophylactic thyroidectomy for asymptomatic siblings with positive 634 codon mutation[J].J Assoc Physicians India,2012,60:127-129.
[43] Gupta N,Dasyam AK,Carty SE,et al.RAS mutations in thyroid FNA specimens are highly predictive of predominantly low-risk follicular-pattern cancers[J].J Clin Endocrinol Metab,2013,98(5):E914-22.
[44] An JH,Song KH,Kim SK,et al.RAS mutations in indeterminate thyroid nodules are predictive of the follicular variant of papillary thyroid carcinoma[J].Clin Endocrinol,2015,82(5):760-766.
[45] Nikiforov YE.Molecular analysis of thyroid tumors[J].Mod Pathol,2011,24(Suppl 2):S34-S43.
[46] Jang EK,Song DE,Sim SY,et al.NRAS codon 61 mutation is associated with distant metastasis in patients with follicular thyroid carcinoma[J].Thyroid,2014,24(8):1275-1281.
[47] Alzahrani AS,Alsaadi R,Murugan AK,et al.TERT promoter mutations in thyroid cancer[J].Horm Cancer,2016,7(3):165-177.
[48] Albarel F,Conte-Devolx B,Oliver C.From nodule to differentiated thyroid carcinoma:contributions of molecular analysis in 2012[J].Ann Endocrinol(Paris),2012,73(3):155-164.